Dear Editor,

We appreciate Dr Beretta and co-workers\' interest in our report. Dr Beretta\'s study confirmed a part of our conclusions: in our short communication no statistical significant differences were found between SSc patients and healthy controls with respect to the -597 (-174) allele distribution \[[@b1]\]. The data communicated by Dr Beretta are based on a valid power calculation and therefore rule out, with a probability of 75%, the possibility of a statistically significant difference of 9% or higher of the prevalence of the G allele in the position -174 of the IL-6 promoter between healthy controls and SSc patients from Italy. Our short communication presented the data of a pilot-study, whose aim was to investigate any possible association between the 597 single nucleotide polymorphism (SNP) of the IL-6 promoter and either the susceptibility to SSc or any clinical characteristics of this disease. Following these preliminary data, our group is about to complete a larger, multicentric study on the association of SSc and IL-6 genetic polymorphisms and we shall soon be able to publish new data, sustained by a satisfactory power calculation.

Using the same method as in our report \[[@b1]\], the larger study by Beretta et al. failed to find any association of the G allele in the position -174 of the IL-6 pr with higher disease activity and disease-induced disability. Due to the large number of subjects in the Italian cohort, this lack of association is very improbable to be due to a type II error.

We completely agree that HAQ-DI and EScSG disease activity score are dynamic measures that vary in the course of the disease. However, we consider that these scores, and especially the HAQ-DI, reflect the patients\' condition on a larger period of time.

In the study of Clements et al. on the value of the HAQ-DI as a predictor and correlate of outcome in their D-penicillamine trial in SSc patients, the mean change in HAQ-DI over 2 years in 68 patients who completed the study (all having received active treatment in two different doses) was 0.17, approximately 17% of the mean baseline value \[[@b2]\]. In the large cohort of Steen and Medsger, including 1250 SSc patients, there was little change in the mean HAQ-DI over time in the group as a whole, and only selected subsets showed significant and meaningful changes in HAQ-DI within 3 months \[[@b3]\]. It has been shown by Clements and coworkers that impaired fist closure and reduced handspread are among the main correlates of disability in SSc \[[@b4]\], which suggest that at least part of the HAQ-DI accounts for damage produced by the disease. In the absence of strong longitudinal data, allowing an analysis of genetic influence on disease course, it is thus not senseless to study the influence of the -597 IL-6 pr polymorphism on the HAQ-DI.

As for the EScSG activity score, we couldn\'t find any studies on its changes over time. It is already known that SSc patients have greater disease activity during the first years since disease onset \[[@b4]\] although this hasn\'t been studied by the means of the EScSG disease activity score.

Even if the clinical parameters chosen for the polymorphism gene association (HAQ-DI, EScSG) could be discussed, both studies took into account these parameters. The difference in the results of the two studies might also appear due to demographic differences between the two groups of SSc patients. Our study described a group of younger patients (44.4 ±10.7 years versus59.6 ± 12.4 years), with a shorter disease duration (6.8 ± 6.2 years versus11.2 ± 6.8 years) than the group of patients analyzed in Dr Beretta\'s study.

We agree with Dr Beretta\'s conclusions that at the moment we can not definitively rule out the possibility that the G/C -597 (-174) SNP might be associated with different aspects of the disease. The influence of the -597 IL-6 pr polymorphism on disease activity and disease-induced disability may be confirmed by longitudinal studies, showing a different disease course on the long-term between subjects with different genotypes, in order to prove the influence of the above-mentioned polymorphism on disease prognosis. Such a study has to be carried out prospectively, as the evaluation of disability and disease activity cannot be performed on retrospective patient data, to ensure sufficient follow-up (at least 1--2 years) and of course to have sufficient statistical power.
